A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

Capecitabine, a prodrug of 5-FU, has been reported to generate maximal tumour activity at tumour sites and/or to improve drug tolerability as compared with 5-FU infusion, and it has also been demonstrated to act synergistically with irinotecan against some solid cancers. A previous study concluded t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Oh, S C, Sur, H Y, Sung, H J, Choi, I K, Park, S S, Seo, J H, Jeen, Y T, Chun, H J, Shin, S W, Mok, Y J, Kim, J S, Kim, Y H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2007
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2359951/
https://ncbi.nlm.nih.gov/pubmed/17473829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados